aibio
Legal ·
European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer
The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded.
ENTA Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals (ENTA) news ENTA offering and lawsuit news
Latest Enanta Pharmaceuticals news
- Financings
Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales
The company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales.
- Financings
Enanta launches $50,000,000 stock offering, later prices $65,000,000
The preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses.
- Legal
Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court
Enanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given.
Enanta Pharmaceuticals annual financials
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $106.7 million | $131.5 million |
| Net income (loss) | -$81.9 million | -$116.0 million |
| Cash from operations | -$19.3 million | -$78.8 million |
| Cash and equivalents | $32.3 million | $37.2 million |
| Short-term investments | $156.6 million | $211.0 million |
Questions about Enanta Pharmaceuticals
Has Enanta Pharmaceuticals raised money recently?
Our latest story on this, dated Jul 2, 2026: "Enanta Pharmaceuticals files for up to $75,000,000 at-the-market stock sales". The story links the filing or release it is based on. Read the story.
Is Enanta Pharmaceuticals involved in a lawsuit?
Our latest story on this, dated Aug 20, 2025: "Enanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Enanta Pharmaceuticals?
Enanta Pharmaceuticals, Inc. trades under the ticker ENTA on NASDAQ.
Where is Enanta Pharmaceuticals listed?
Enanta Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9EP.
What is the SEC CIK of Enanta Pharmaceuticals?
The SEC Central Index Key (CIK) for Enanta Pharmaceuticals, Inc. is 1177648. Its filings are on SEC EDGAR.
How many shares does Enanta Pharmaceuticals have outstanding?
29,125,402 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Enanta Pharmaceuticals listed under?
Our directory records Enanta Pharmaceuticals, Inc. under United States.
What does Enanta Pharmaceuticals do?
Our directory classifies Enanta Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Enanta Pharmaceuticals?
The ISIN recorded for Enanta Pharmaceuticals, Inc. is US29251M1062.
Does aibio.space cover Enanta Pharmaceuticals?
aibio.space lists Enanta Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Enanta Pharmaceuticals profitable?
Enanta Pharmaceuticals, Inc. reported a net loss of $81.9 million for the fiscal year ended Sep 30, 2025, and used $19.3 million of cash in operations, per its annual report to the SEC.
How much does Enanta Pharmaceuticals spend on research and development?
$106.7 million in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does Enanta Pharmaceuticals have?
$189.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Enanta Pharmaceuticals (ENTA) stock news?
Our latest story on Enanta Pharmaceuticals, dated Oct 29, 2026: "European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer". The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded. Source.
Is Enanta Pharmaceuticals a smaller reporting company?
SEC records list Enanta Pharmaceuticals, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Investor discussion: Enanta Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Enanta Pharmaceuticals Inc
- CIK
- 1177648
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ENTA (Nasdaq)
- Fiscal year ends
- September 30
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
- Phone
- 617 607 0800
- Shares outstanding
- 29,125,402 as of 2026-08-07 (10-Q filed 2026-08-12)
Recent filings
Listing details
- Company
- Enanta Pharmaceuticals, Inc.
- Ticker
- ENTA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US29251M1062
- Other listed symbols
- GETTEX:9EP
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction